Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention

Abstract

The introduction of drug-eluting stents has revolutionized the field of interventional cardiology, since it has reduced the incidence of restenosis by 50–70%. However, recent worrisome data from registries and meta-analyses emphasized higher rates of late and very late stent thrombosis associated with drug-eluting stents. The recently introduced titanium-nitride-oxide-coated stent (Titan-2) has demonstrated an excellent biocompatibility, as reflected by lower rates of platelet aggregation and fibrin deposition, and better endothelialization. Preclinical and clinical trials and registries involving both real-life unselected populations and populations with the most challenging patient and lesion characteristics have shown a low rate of major adverse cardiac events in the long-term, with a restenosis rate comparable with that of drug-eluting stents, with the virtual absence of stent thrombosis.

Keywords::

• bioactive stents
• drug-eluting stents
• in-stent restenosis
• percutaneous coronary intervention
• stent thrombosis

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.